Due to concerns about liver toxicity, it has been recommended that liver enzymes be checked in patients beginning statin therapy and periodically thereafter. In clinical trials, mild transaminase elevations have been common both in patients on statins and in control groups. Serious liver toxicity from statins is rare. It remains controversial to what extent, if any, the recommended screening for underlying liver disease or statin-induced hepatotoxicity is beneficial.
South Med J. 2006;99(3):250-254. © 2006 Lippincott Williams & Wilkins
Cite this: Primary Evaluation and Management of Statin Therapy Complications - Medscape - Mar 01, 2006.